IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) Files An 8-K Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement.

On April 13, 2017, Imprimis Pharmaceuticals, Inc. (the Company)
entered into a Strategic Sales Marketing Agreement (the
Agreement) with Cameron Ehlen Group, Inc. dba Precision Lens
(Precision Lens). to the terms of the Agreement, Precision Lens
will provide exclusive sales and marketing representation
services to the Company in select geographies in the U.S.
Midwest, in connection with the Companys ophthalmic compounded
formulation portfolio including its Dropless Therapy, LessDrops
combination eye drops, Simple Drops preservative-free glaucoma
drops, MKO Melt conscious sedation and other ocular-related
formulations typically used for dilation, general inflammation
and infection (the Products).

Under the terms of the Agreement, the Company is required to make
commission payments to Precision Lens equal to ten percent (10%)
of each calendar years annual net sales for Products above and
beyond the Companys initial $1,500,000 in annual net sales for
Products for each calendar year. In addition, the Company is
required to make certain periodic milestone payments to Precision
Lens in shares of the Companys restricted common stock including:
(i) 10,000 shares if net sales for Products reach $5,000,000
prior to December 31, 2017; (ii) 15,000 shares if net sales for
Products reach $5,000,000; (iii) 15,000 shares if net sales for
Products reach $10,000,000; (iv) 15,000 shares if net sales for
Products reach $15,000,000; and (v) 15,000 shares if net sales
for Products reach $20,000,000.

The foregoing is only a brief description of the Agreement does
not purport to be a complete description of the rights and
obligations of the parties thereunder and is qualified in its
entirety by reference to the full text of the document, which is
filed as Exhibit 10.1 to this Current Report on Form 8-K and is
incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

About IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY)

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) Recent Trading Information

IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) closed its last trading session up +0.02 at 3.79 with 149,930 shares trading hands.